$105.51
0.06% today
Nasdaq, Aug 22, 04:48 pm CET
ISIN
US9250501064
Symbol
VRNA

Verona Pharma plc Sponsored ADR Stock News

Positive
The Motley Fool
22 days ago
Investing in index funds is a safe way to grow your portfolio over the years. But there's a huge advantage to picking individual stocks: Your returns can be massive and life-changing.
Neutral
Business Wire
about one month ago
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Verona Pharma plc (NasdaqGM: VRNA) to Merck & Co., Inc. (NYSE: MRK). Under the terms of the proposed transaction, shareholders of Verona will receive $107.00 in cash for each share of American Depositor...
Positive
Reuters
about one month ago
Merck is acquiring UK-based Verona Pharma for about $10 billion, as part of the U.S. drugmaker's strategy to diversify beyond its blockbuster cancer treatment Keytruda.
Neutral
Business Wire
about one month ago
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Verona Pharma plc (NASDAQ: VRNA) to Merck for $107.00 per American Depository Share is fair to Verona shareholders. Halper Sadeh encourages Verona shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 o...
Positive
Invezz
about one month ago
Verona Pharma Plc (NASDAQ: VRNA) rallied about 20% on Wednesday after Merck & Co Inc (NYSE: MRK) said it will buy the UK-based biotech firm known for its COPD drug Ohtuvayre. The $10 billion all-cash agreement values VRNA shares at $107 each, representing about a 23% premium on their previous close.
Positive
WSJ
about one month ago
The move bolsters Merck's lineup as it braces for the 2028 loss of patent exclusivity for blockbuster cancer drug Keytruda.
Neutral
Investors Business Daily
about one month ago
Merck said Wednesday it would buy COPD drugmaker Verona Pharma for $10 billion. The news sent Verona stock flying.
Positive
Invezz
about one month ago
Merck announced Wednesday it will acquire UK-based Verona Pharma for approximately $10 billion, deepening its commitment to respiratory treatments as the company prepares for a revenue gap following the patent expiry of its cancer blockbuster, Keytruda. This marks Merck's largest transaction since its $10.

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today